Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery

被引:32
|
作者
Lai, Xianyin [1 ]
Tang, Jason [1 ]
ElSayed, Mohamed E. H. [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Biotechnol Discovery Res, Indianapolis, IN 46285 USA
关键词
Proteolytic stability; peptide; protein; antibody; peptidase; cleavage site; amino acid replacement; GLUCAGON-LIKE PEPTIDE-1; COLONY-STIMULATING FACTOR; BETA-AMINO ACIDS; SUBSTRATE-SPECIFICITY; ASYMMETRIC-SYNTHESIS; RECEPTOR AGONISTS; SALMON-CALCITONIN; ORAL ABSORPTION; ACTIVE-SITE; DEGRADATION;
D O I
10.1080/17460441.2021.1942837
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: To discover and develop a peptide, protein, or antibody into a drug requires overcoming multiple challenges to obtain desired properties. Proteolytic stability is one of the challenges and deserves a focused investigation. Areas covered: This review concentrates on improving proteolytic stability by engineering the amino acids around the cleavage sites of a liable peptide, protein, or antibody. Peptidases are discussed on three levels including all peptidases in databases, mixtures based on organ and tissue types, and individual peptidases. The technique to identify cleavage sites is spotlighted on mass spectrometry-based approaches such as MALDI-TOF and LC-MS. For sequence engineering, the replacements that have been commonly applied with a higher chance of success are highlighted at the beginning, while the rarely used and more complicated replacements are discussed later. Although a one-size-fits-all approach does not exist to apply to different projects, this review provides a 3-step strategy for effectively and efficiently conducting the proteolytic stability experiments to achieve the eventual goal of improving the stability by engineering the molecule itself. Expert opinion: Improving the proteolytic stability is a spiraling up process sequenced by testing and engineering. There are many ways to engineer amino acids, but the choice must consider the cost and properties affected by the changes of the amino acids.
引用
收藏
页码:1467 / 1482
页数:16
相关论文
共 50 条
  • [31] Recent Advances in Quantum Computing for Drug Discovery and Development
    Kumar, Gautam
    Yadav, Sahil
    Mukherjee, Aniruddha
    Hassija, Vikas
    Guizani, Mohsen
    IEEE ACCESS, 2024, 12 : 64491 - 64509
  • [32] Recent Strategic Advances in CFTR Drug Discovery: An Overview
    Rusnati, Marco
    D'Ursi, Pasqualina
    Pedemonte, Nicoletta
    Urbinati, Chiara
    Ford, Robert C.
    Cichero, Elena
    Uggeri, Matteo
    Orro, Alessandro
    Fossa, Paola
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (07)
  • [33] Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances
    Reis, Joana
    Gaspar, Alexandra
    Milhazes, Nuno
    Borges, Fernanda
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (19) : 7941 - 7957
  • [34] Recent Advances in Physicochemical and ADMET Profiling in Drug Discovery
    Wang, Jianling
    Skolnik, Suzanne
    CHEMISTRY & BIODIVERSITY, 2009, 6 (11) : 1887 - 1899
  • [35] Recent Advances in Quantum Computing for Drug Discovery and Development
    Wang, Pei-Hua
    Chen, Jen-Hao
    Yang, Yu-Yuan
    Lee, Chien
    Tseng, Yufeng Jane
    IEEE NANOTECHNOLOGY MAGAZINE, 2023, 17 (02) : 26 - 30
  • [36] Targeting Autophagy In Disease: Recent Advances In Drug Discovery
    Kim, Dasol
    Hwang, Hui-Yun
    Kwon, Ho Jeong
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (09) : 1045 - 1064
  • [37] Decision support for drug discovery: Some recent advances
    Murcko, Mark
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [38] Recent Advances in Drug Discovery and Treatment of Neglected Diseases
    Lago, Joao H. G.
    Domingues Passero, Luiz Felipe
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2022, 22 (19) : 1593 - 1594
  • [39] Recent advances of quinones as a privileged structure in drug discovery
    Zhang, Li
    Zhang, Guiying
    Xu, Shujing
    Song, Yuning
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223
  • [40] Recent advances in drug discovery for diabetic kidney disease
    Danta, Chhanda Charan
    Boa, Andrew N.
    Bhandari, Sunil
    Sathyapalan, Thozhukat
    Xu, Shang-Zhong
    EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (04) : 447 - 461